Cyprus Mail
BusinessHealthcareInternational

AstraZeneca gets EU backing for targeted breast cancer therapies

file photo: the company logo for pharmaceutical company astrazeneca is displayed on a screen on the floor at the nyse in new york, united states
The company logo for pharmaceutical company AstraZeneca displayed on a screen at the New York Stock Exchange

AstraZeneca (AZN.L) said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio.

Lynparza, a cancer drug developed jointly with US-based Merck (MRK.N), was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.

The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies.

Enhertu, developed jointly with Japan’s Daiichi Sankyo (4568.T), was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

Enhertu is seen as a major growth driver for AstraZeneca, with some analysts expecting peaks sales of $10 billion. The drug is also expected to be cleared for patients with low levels of HER2 this month after the recent success of a trial.

Follow the Cyprus Mail on Google News

Related Posts

BlockDAG’s keynote dissects BDAG’s journey to $600m as Market Experiences Another Surge With XRP & GALA

CM Guest Columnist

Cyprus consumer prices increase in February

Souzana Psara

CySEC joins global forces in promoting financial literacy

Souzana Psara

Oil prices edge lower but set to end week over 3 per cent higher

Reuters News Service

Larnaca designated as city with best investment opportunities

Kyriacos Nicolaou

Bank of England set to play for time before first rate cut

Reuters News Service